Comparative animal models for the study of lymphohematopoietic tumors: Strengths and limitations of present approaches

Leukemia and Lymphoma

Volumn 46, Issue 7, 2005, Pages 973-992

  O'Connor, Owen A ^a   Toner, Lorraine E ^a   Vrhovac, Radovan ^a   Budak Alpdogan, Tulin ^b   Smith, Emily A ^a   Bergman, Philip ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c ANIMAL MEDICAL CENTER   (United States)

Author keywords

Comparative animal models; Dos models; Lymphoma; Mouse models

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CD19 ANTIBODY; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IMMUNOTOXIN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; RADIOPHARMACEUTICAL AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CANCER CELL; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER MODEL; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GRAFT SURVIVAL; HUMAN; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 22144473694     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500083193     Document Type: Review

References (246)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics 2004. CA: Cancer J Clin 2004;54:8-29.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA: Cancer J Clin 1998;48:6-30.
3. Skarin AT, Dorfman DM. Non-Hodgkin's lymphomas: current classification and management. CA: Cancer J Clin 1997;47:351-372.
4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Am J Clin Oncol 1999;17:3835-3849.
5. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
6. Pantelouris EM. Absence of thymus in a mouse mutant. Nature 1968;217:370-371.
7. Rygaard J, Povlsen CO. Heterotransplantation to a human malignant tumour to 'Nude' mice. Acta Pathol et Microbiol Scand 1969;77:758-760.
8. Steel GG, Courtenay VD, Peckham MJ. The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 1983;47:1-13.
9. Winograd B, Boven E, Lobbezoo MW, Pinedo HM. Human tumor xenografts in the nude mouse and their value as test models in cancer drug development. In Vivo 1987;1:1-13.
10. Boven E. Characterization and monitoring. In Boven E, Winograd B, editors. The nude mouse on oncology research. Florida: CRC Press Inc.; 1991. pp. 89-101.
11. Cattan AR, Douglas E. The C. B.17 scid mouse strain as a model for human disseminated leukemia and myeloma in vivo. Leuk Res 1994;18:513-522.
12. Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey JH. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res 1992;52:1314-1321.
13. Molthoff CFM, Calame JJ, Pinedo HM, Boven E. Human ovarian xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 1991;47:72-79.
14. Xie X, Brunner N, Jensen G, Albrectsen J, Gotthardsen B, Rygaard J. Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metast 1992;10:201-210.
15. Brunner N, Spang-Thomsen M, Skovgaard-Poulsen H, Engelholm SA, Nielsen A, Vindelov L. Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude mice. Int J Cancer 1985;35:59-64.
16. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985;45:584-590.
17. Van Steenbrugge GJ, Blankenstein MA, Bolt-de Vries J, Romijn JC, Schroder FH, Vihko P. Effect of hormone treatment on prostatic acid phosphatase in a serially transplantable human prostatic adenocarcinoma (PC-82). J Urol 1983;129:630-633.
18. Maruo K, Ueyama Y, Hioki K, Saito M, Nomura T, Tamaoki N. Strain-dependent growth of a human carcinoma in nude mice with different genetic backgrounds: selection of nude mouse strains useful for anticancer agent screening system. Exp Cell Biol 1982;50:115-119.
19. Epstein AL, Herman MM, Kim H, Dorfman RF, Kaplan HS. Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse. Cancer 1976;37:2158-2176.
20. Giovanella BC, Morgan AC, Stehlin JS, Williams LJ, Mimford BC. Development of invasive tumors in 'nude' thymusless mice injected with human cells cultured from Burkitt lymphomas'. Proc Am Assoc Cancer Res 1973;14:20-28.
21. Nilsson K, Giovanella BC, Stehlin JS, Klein G. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer 1977;19:337-344.
22. Povlsen CO, Fialkow PJ, Klein E, Klein G, Rygaard J, Wiener F. Growth and antigenic properties of a biopsy derived Burkitt's lymphoma in thymusless (nude) mice. Int J Cancer 1973;11:30-39.
23. Schaadt M, Kirchner H, Fonatsch C, Diehl V. Intracranial heterotransplantation of human hematopoietic cells in nude mice. Int J Cancer 1979;23:751-761.
24. Watanebe S, Shimosato Y, Kameya T, Kuroki M, Kitahara T, Minato K. Leukemic distribution of a human acute lymphocytic leukemia cell line (Ichikawa strain) in nude mice conditioned with whole body irradiation. Cancer Res 1978;38:3493-3498.
25. Watanebe S, Shimosato Y, Kuroki M, Sato Y, Nakajima T. The transplantability of human lymphoid cell line, lymphoma, and leukemia in splenectomized and/or irradiated nude mice. Cancer Res 1980;40:2588-2595.
26. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple defects. Leukemia 1998;12:2029-3203.
27. Ghetie MA, Gordon BE, Podar EM, Vitetta ES. Effect of sublethal irradiation of SCID mice on growth of B-cell lymphoma xenografts and on efficacy of chemotherapy and/or immunotoxin therapy. Lab Anim Sci 1996;46:305-309.
28. Haller O, Kiessling R, Orn A, Karre K, Nilsson K, Wigzell H. Natural cytotoxicity to human leukemia mediated by mouse non-T cells. Int J Cancer 1997;20:93-103.
29. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16:216-229.
30. Herberman RB, Nunn ME, Holden HT, Stall S, Djeu JY. Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer 1977;19:555-564.
31. Klein AS, Plata F, Jackson MJ, Shin S. Cellular tumorigenicity in nude mice. Role of susceptibility to natural killer cells. Exp Cell Biol 1979;47:430-445.
32. Kristensen E. Natural cytotoxicity: relationship to tumorigenicity of human cell lines in nude mice. Proc Soc Exp Biol Med Soc Exp Biol Med NY 1979;162:467-470.
33. McCormick KH, Giovanella BC, Klein G, Nilsson K, Stehlin JS. Diploid human lymphoblastoid and Burkitt lymphoma cell lines: susceptibility to murine NK cells and heterotransplantation to nude mice. Int J Cancer 1981;28:455-458.
34. Nunn ME, Herberman RB, Holden HT. Natural cell-mediated cytotoxicity in mice against non-lymphoid tumor cells and some normal cells. Int J Cancer 1977;20:381-387.
35. Warner NL, Woodruff MFA, Burton RC. Inhibition of the growth of lymphoid tumors in syngeneic athymic (nude) mice. Int J Cancer 1977;20:146-155.
36. Sharp AK, Colston MJ. The regulation macrophage activity in congenitally athymic mice. Eur J Immunol 1984;14:102-105.
37. Vetvicka V, Fornusek L, Holub M, Zidkova J, Kopecek J. Macrophages of athymic nude mice: Fc receptors, C receptors, phagocytic and pinocytic activities. Eur J Cell Biol 1984;35:35-40.
38. Faguet GB, Agee JF. Transplantation of human hairy cell leukemia in radiation-preconditioned nude mice: characterization of the model by histological, histochemical, phenotypic, and tumor kinetic studies. Blood 1988;71: 1511-1517.
39. Martin WJ, Martin SE. Naturally occurring cytotoxic antitumor antibodies in sera of congenitally athymic (nude) mice. Nature 1974;249:564-565.
40. Campanile F, Crino L, Bonmassar E, Houchens E, Goldin A. Radioresistant inhibition of lymphoma growth in congenitally athymic (nude) mice. Cancer Res 1977;37:394-398.
41. Arnstein P, Taylor DO, Nelson-Rees WA, Huebner J, Lennette EH. Propagation of human tumors in antithymocyte serum-treated mice. J Natl Cancer Inst 1974;52:71-84.
42. Detre SI, Gazet JC. Transplantation of human tumour to immune deprived mice treated with anti-thymocyte serum. Br J Cancer 1973;28:412-416.
43. Phillips B, Gazet JC. Effect of antilymphocyte serum on the growth of Hep2 and HeLa cells in mice. Nature 1968;220:1140-1141.
44. Cobb LM. The behaviour of carcinoma of the large bowel in man following transplantation into immune deprived mice. Br J Cancer 1973;28:400-411.
45. Cobb LM, Mitchley BC. The growth of human tumours in immune deprived mice. Eur J Cancer Clin Oncol 1974;10: 473-476.
46. Franks CR, Perkins FT, Homes JT. Subcutaneous growth of human tumours in mice. Nature 1973;243:91-99.
47. Franks CR, Bishop D, Reeson D. The growth of tumour xenografts in thymectomized high dose irradiated mice reconstituted with syngeneic bone marrow cells incubated with anti-thymocyte serum. Br J Cancer 1976;33:112-115.
48. McManaway ME, Marti GE, Tosato G, Liu AK, al-Nasser A, Kiwanuka J, Magrath IT. Heterotransplantation of human Burkitt's lymphoma cell lines in athymic nude mice: tumor-host relationships. Pathobiology 1993;61:164-172.
49. Ohsugi Y, Gershwin ME, Owens RB, Nelson-Rees WA. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice and X-irradiated nude mice. J Natl Cancer Inst 1980;65:715-718.
50. Sudo K. Improvement of transplantability of human neoplastic cells to nude mice. Jpn J Exp Med 1987;57:189-192.
51. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, Suit HD. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficiency mice. Cancer Res 1993;53: 5012-5017.
52. Ziegler HW, Frizzera G, Bach FH. Successful transplantation of a human leukemia cell line into nude mice: conditions optimizing graft acceptance. J Natl Cancer Inst 1982;68: 15-18.
53. Zubair AC, Ali SA, Rees RC, Goepel Jr, Winfield DA, Goyns MH. Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells. Leukemia Lymphoma 1996;22: 463-471.
54. Braakhuis BJ, Nauta MM, Romijn JC, Rutgers DH, Smink T. Enhanced success rate of transplantation with human tumors in cyclophosphamide-treated nude mice. J Natl Cancer Inst 1986;76:241-245.
55. Harkonen S, Mischak R, Lopez H, Stoudemire J. Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats. Cancer Drug Deliv 1987;4:151-157.
56. Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1993;7:290-297.
57. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N. In vivo effects of anti-asialo GM. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981;127:34-38.
58. Kawase I, Urdal DL, Brooks CG, Henney CS. Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants. Int J Cancer 1982;29:567-574.
59. Keller R, Bachi T, Okumura K. Discrimination between macrophage-and NK-type tumoricidal activities via anti-asialo GM1 antibody. Exp Cell Biol 1983;51:158-164.
60. Aamdal S, Fodstad O, Nesland JM, Pihl A. Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice. Br J Cancer 1985;51: 347-356.
61. Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 1988;41:442-449.
62. Giavazzi R, Campbell DE, Jessup JM, Cleary K, Fidler IJ. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986;46:1928-33.
63. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984;44:5286-5290.
64. Kjonniksen I, Nesland JM, Pihl A, Fodstad O. Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst 1990;82:408-412.
65. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer 1984;44:3522-3529.
66. McLemore TL, Eggleston JC, Shoemaker RH, Abbott BJ, Bohlman ME, Liu MC, Fine DL, Mayo JG, Boyd MR. Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res 1988;48:2880-2886.
67. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 1986;46:4109-4115.
68. Povlsen CO. Heterotransplantation of human malignant melanomas to the mouse mutant nude. Acta Pathol Microbiol Scand 1976;84:9-16.
69. White AC, Levy JA, McGrath CM. Site-selective growth of a hormone-responsive human breast carcinoma in athymic mice. Cancer Res 1982;42:906-912.
70. Naito S, von Eschenbach AC, Fidler IJ. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J Natl Cancer Inst 1987;78:377-385.
71. Rodolfo M, Balsari A, Clemente C, Parmiani G, Fossati G. Tumorigenicity and dissemination of primary and metastatic human melanomas implanted intodifferent sites in athymic nude mice. Invasion Metastasis 1988;8:317-331.
72. Liu Q, Zhao W, Tuo C, Wang Z, Wu B, Zhang N (2002) Establishment and characteristics of orthotopically transplanted model of human primary malignant spleen lymphoma in nude mice. Zhonghua Zhong Liu Za Zhi 2002;24:234-238.
73. Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esher HJ. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 1979;47:281-293.
74. Bennett JA, Pilon VA, MacDowell RT. Evaluation of growth and histology of human tumor xenografts implanted under the renal capsule of immunocompetent and immunodeficient mice. Cancer Res 1985;45:4963-4969.
75. Panje WR, McCormick KJ. Murine subrenal capsule assay: prediction of chemoresponsiveness in head and neck cancer. Laryngoscope 1989;99:41-49.
76. Parnes SM, Bennett JA, Deconti RC, Sagerman P. Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth chemosensitivity of human squamous head and neck carcinomas. Eur J Surg Oncol 1989;42:21-27.
77. Stratton JA, Kucera PR, Micha JP, Rettenmaier MA, Braly PS, Berman ML, DiSaia PJ. The subrenal capsule tumor implant assay as a predictor of clinical response to chemotherapy: 3 years of experience. Gynecol Oncol 1984; 19:336-347.
78. Yamada H. Histological take rates of fresh human tumors in the subrenal capsular space of cyclosporin A treated mice. Gan To Kagaku Ryoho 1989;16:2613-269.
79. Cattan AR, Maung ZT. A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines. Cancer Chemother Pharmacol 1996;38:548-552.
80. de Kroon JF, Kluin PM, Kluin-Nelemans HC, Willemze R, Falkenburg JH. Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice. Leukemia 1994; 8:1385-1391.
81. Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res 1994;54:2688-2694.
82. Terpstra W, Prins A, Visser T, Wognum B, Wagemaker G, Lowenberg B, Wielenga J. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia 1995;9:1573-1577.
83. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta. ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 1990;45: 481-485.
84. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman MH, Phillips RA, Dick JE. A model of human acute lymphoblastic leukemia in immunedeficient SCID mice. Science 1989;246:1597-1600.
85. Saini M, Bellinzona M, Weichhold W, Samii M. A new xenograft model of primary central nervous system lymphoma. J Neurooncol 1999;43:153-160.
86. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530.
87. Cavacini LA, Giles-Komar J, Kennel M, Quinn A. Effect of immunosuppressive therapy on cytolytic activity of immunodeficient mice: implications for xenogeneic transplantation. Cellular Immunol 1992;144:296-310.
88. Itoh T, Shiota M, Takanashi M, Hojo I, Satoh H, Matsuzawa A, Moriyama T, Watanabe T, Hirai K, Mori S. Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer 1993;72:2686-2694.
89. Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992;255:1137-1141.
90. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988;241:1632-1639.
91. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256-259.
92. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol 1988;140:3801-3807.
93. Lowry PA, Shultz LD, Greiner DL, Hesselton RM, Kittler EL, Tiarks CY, Rao SS, Reilly J, Leif JH, Ramshaw H, Stewart FM, Quesenberry PJ. Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol Blood Marrow Transplant 1996;2:15-23.
94. Steele JP, Clutterbuck RD, Powles RL, Mitchell PL, Horton C, Morilla R, Catovsky D, Millar JL. Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice. Blood 1997;90:2015-2019.
95. Moore MAS, MacKenzie KL. Optimizing conditions for gene transfer into human hematopoietic cells. In: Bertino JR, editor. Marrow protection. Basel: Karger AG; 1999. pp. 20-49.
96. Uchiyama T. ATL and HTLV-I: in vivo cell growth of ATL cells. J Clin Immunol 1996;16:305-314.
97. Leonard JE, Johnson DE, Felsen RB, Tanney LE, Royston I, Dillman RO. Establishment of a human B-cell tumor in athymic mice. Cancer Res 1987;47:2899-2902.
98. Horgan K, Jones DL, Mansel RE. Mitogenicity of human fibroblasts in vivo for human breast cancer. Br J Surg 1987;74:227-229.
99. Picard O, Rolland Y, Poupon MF. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res 1986;46: 3290-3294.
100. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med 1990;172:1055-1063.
101. Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992;79:1704-1711.
102. Rombouts WJ, Martens AC, Ploemacher RE (2000) Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000;14:889-897.
103. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-765.
104. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913.
105. Povlsen CO, Visfeldt J, Rygaard J, Jensen G. Growth patterns and chromosome constitutions of human malignant tumours after long-term serial transplantation in nude mice. Acta Pathol Microbiol Scand 1976;83:709-716.
106. Bryant J, Pham L, Yoshimura L, Tamayo A, Ordonez N, Ford RJ (2000) Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models. Lab Invest 2000;80:557-573.
107. Charley MR, Tharp M, Locker J, Deng JS, Goslen JB, Mauro T, McCoy P, Abell E, Jegasothy B. Establishment of a human cutaneous T-cell lymphoma in C. B-17 SCID mice. J Invest Dermatol 1990;94:381-384.
108. Feuer G, Zack JA, Harrington W. J. Jr., Valderama R, Rosenblatt JD, Wachsman W, Baird SM, Chen IS. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood 1993;82:722-731.
109. Flavell DJ. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Hematol Oncol 1996;14:67-82.
110. Imada K, Takaori-Kondo A, Akagi T, Shimotohno K, Sugamura K, Hattori T, Yamabe H, Okuma M, Uchiyama T. Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo. Blood 1995;86:2350-2357.
111. Kapp U, Wolf J, von Kalle C, Tawadros S, Rottgen A, Engert A, Fonatsch C, Stein H, Diehl V. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Annal Oncol 1992;3:21-23.
112. Kirchner HH, Engert A, Diehl V. Experimental chemotherapy of heterotransplanted Hodgkin- and non-Hodgkin-lymphoma cell lines in nude mice. Behring Inst Mitt 1984;74:329-336.
113. Zamecnik PC, Long JC. Growth of cultured cells from patients with Hodgkin's disease and transplantation into nude mice. Proc Natl Acad Sci USA 1977;74:754-758.
114. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A, Kapp U, Fonatsch C, Komitowski D, Feaux de Lacroix W. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer 1992;52:887-891.
115. Igarashi T, Oka K, Miyamoto T. Human non-Hodgkin's malignant lymphomas serially transplanted in nude mice conditioned with whole-body irradiation. Br J Cancer 1989; 59:356-360.
116. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174:859-866.
117. Blasé L, Daniel PT, Koretz K, Schwartz-Albiez R, Moller P. The capacity of human malignant B-lymphocytes to disseminate in SCID mice is correlated with functional expression of the fibronectin receptor alpha 5 beta 1 (CD49e/CD29). Int J Cancer 1995;60:860-866.
118. Abe M, Suzuki O, Tasaki K, Tominaga K, Wakasa H. Analysis of lectin binding properties on human Burkitt's lymphoma cell lines that show high spontaneous metastasis to distant organs in SCID mice: the binding sites for soybean agglutinin lectin masked by sialylation are closely associated with metastatic lymphoma cells. Pathol Int 1996;46: 977-983.
119. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F (2000) Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000;60:2527-2534.
120. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969.
121. Durandy A, Emilie D, Peuchmaur M, Forveille M, Clement C, Wijdenes J, Fischer A. Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 1994;152:5361-5367.
122. Nadal D, Albini B, Schlapfer E, Bernstein JM, Ogra PL. Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells. J Gen Virol 1992;73: 113-121.
123. Tanner J, Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991;88:239-247.
124. Veronese ML, Veronesi A, Bruni L, Coppola V, D'Andrea E, Del Mistro A, Mezzalira S, Montagna M, Ruffatto G, Amadori A. Properties of tumors arising in SCID mice injected with PBMC from EBV-positive donors. Leukemia 1994;8 (1 Suppl):S214-S217.
125. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995;85: 1063-1074.
126. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 1992;12: 103-110.
127. Funakoshi S, Beckwith M, Fanslow W, Longo DL, Murphy WJ. Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention. Pathobiology 1995;63:133-142.
128. Funakoshi S, Taub DD, Asai O, Hirano A, Ruscetti FW, Longo DL, Murphy WJ. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Leuk Lymphoma 1997;24:187-199.
129. Feuer G, Stewart SA, Baird SM, Lee F, Feuer R, Chen IS. Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. Journal of clinical virology: the official publication of the Pan Am Soc Clin Virol 1995;69:1328-1333.
130. Stewart SA, Feuer G, Jewett A, Lee FV, Bonavida B, Chen IS. HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology 1996;226:167-175.
131. Laurence J, Astrin SM. Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. Proc Natl Acad Sci USA 1991;88:7635-7639.
132. Ishihara S, Okayama A, Nagatomo Y, Murai K, Yamashita R, Okamoto M, Shima T, Sasaki T, Mueller N, Tachibana N, Tsubouchi H. Enhanced engraftment of HTLV-I-infected human T cells in severe combined immunodeficiency mice by anti-asialo GM-1 antibody treatment. Microbiol Immunol 1996;40:39-44.
133. Schwarz MA, Tardelli L, Macosko HD, Sullivan LM, Narula SK, Fine JS. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 1995;55:3692-3696.
134. Weimar IS, Weijer K, van den Berk PC, Muller EJ, Miranda N, Bakker AQ, Heemskerk MH, Hekman A, de Gast GC, Gerritsen WR. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice. Br J Cancer 1999;81:43-53.
135. Waller EK, Kamel OW, Cleary ML, Majumdar AS, Schick MR, Lieberman M, Weissman IL. Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. Blood 1994;78: 2650-2665.
136. Lefebvre D, Gala JL, Heusterspreute M, Delhez H, Philippe M. Introduction of a normal retinoblastoma (Rb) gene into Rb-deficient lymphoblastoid cells delays tumorigenicity in immunodefective mice. Leukemia Res 1998;22:905-912.
137. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 1997;57: 2508-2515.
138. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999;94: 1100-1107.
139. Morris G, DeNardo SJ, DeNardo GL, Leshchinsky T, Wu B, Mack PC, Winthrop MD, Gumerlock PH. Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth. Biochem Mol Med 1997;60:108-115.
140. Imada K, Takaori-Kondo A, Sawada H, Imura A, Kawamata S, Okuma M, Uchiyama T. Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice. Jpn J Cancer Res 1996;87:887-892.
141. Woychik RP, Wassom JS, Kingsbury D. TBASE: a computerized database for transgenic animals and targeted mutations. Nature 1993;363:375-376.
142. Palmiter RD, Brinster RL. Germ-line transformation of mice. Ann Review Genet 1986;20:465-499.
143. Wood SA, Pascoe WS, Schmidt C, Kemler R, Evans MJ, Allen ND. Simple and efficient production of embryonic stem cell-embryo chimeras by coculture. Proc Natl Acad Sci USA 1993;90:4582-4585.
144. Russell WL, Kelly PR, Hunsicker PR, Bangham JW, Maddux SC, Phipps EL. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. Proc Natl Acad Sci USA 1979;76:5918-5922.
145. Bernardi R, Grisendi S, Pandolfi PP. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene 2002;21:3445-3458.
146. Seldin DC. New models of lymphoma in transgenic mice. Curr Opinion Immunol 1995;7:665-673.
147. Schmitt CA, Lowe SW (2002) Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 2002;80: 137-146.
148. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE (2000) The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis. Oncogene 2000;19:968-988.
149. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999;13:2670-2677.
150. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-2669.
151. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40: 307-318.
152. Moulton JE, Harvey JW. Tumors of lymphoid and hematopoietic tissue. In: Moulton JE, editors. Tumors of domestic animals. Berkeley: University of California Press; 1990. pp. 231-307.
153. MacEwen EG, Patnaik AK, Wilkins RJ. Diagnosis and treatment of canine hematopoietic neoplasms. Vet Clin North Am 1977;7:105-118.
154. Parodi A, Wyers M, Paris J. Incidence of canine lymphoid leukosis. Age, sex and breed distribution; results of a necropsic survey. Bibl Haematol 1968;30:263-267.
155. Onions DE. A prospective survey of familial canine lymphosarcoma. J Natl Cancer Inst 1984;72:909-912.
156. Teske E, de Vos JP, Egberink HF, Vos JH. Clustering in canine malignant lymphoma. Vet Q 1994;16:134-136.
157. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Location: National Cancer Institute monograph; Washington, DC, 1980. pp. 1-210.
158. Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin's lymphoma. Vet Q 1994;16:209-219.
159. Blair A. Herbicides and non-Hodgkin's lymphoma: new evidence from a study of Saskatchewan farmers. J Natl Cancer Inst 1990;82:544-545.
160. Hardell L, Eriksson M, Lenner P, Lundgren E. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study. Br J Cancer 1981;43:169-176.
161. Hardell L, Axelson O. Environmental and occupational aspects on the etiology of non-Hodgkin's lymphoma. Oncol Res 1998;10:1-5.
162. Hayes HM, Tarone RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC. Case-control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 1991;83:1226-1231.
163. Hayes HM, Tarone RE, Cantor KP. On the association between canine malignant lymphoma and opportunity for exposure to 2,4-dichlorophenoxyacetic acid. Environ Res 1995;70:119-125.
164. Reynolds PM, Reif JS, Ramsdell HS, Tessari JD. Canine exposure to herbicide-treated lawns and urinary excretion of 2,4-dichlorophenoxyacetic acid. Cancer Epidemiol Biomark Prevent 1994;3:233-237.
165. Hahn KA, Richardson RC, Hahn EA, Chrisman CL. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Pathol 1994;31:528-540.
166. Owen LN, Bostock DE, Halliwell RE. Cell-mediated and humoral immunity in dogs with spontaneous lymphosarcoma. Eur J Cancer 1975;11:187-191.
167. Weiden PL, Storb R, Kolb HJ, Ochs HD, Graham TC, Tsoi MS, Schroeder ML, Thomas ED. Immune reactivity in dogs with spontaneous malignancy. J Natl Cancer Inst 1974; 53:1049-1056.
168. Keller ET. Immune-mediated disease as a risk factor for canine lymphoma. Cancer 1992;70:2334-2337.
169. Teske E, Rutteman GR, Kuipers-Dijkshoorn NJ, van Dierendonck JH, van Heerde P, Cornelisse CJ. DNA ploidy and cell kinetic characteristics in canine non-Hodgkin's lymphoma. Exp Hematol 1993;21:579-584.
170. Carter RF, Valli VE, Lumsden JH. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Can J Vet Res 1986;50:154-164.
171. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI, Lieberman PH. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990;66:480-490.
172. Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975;31 (2 Suppl):29-43.
173. Rappaport H. Comparative aspects of hematopoietic neoplasms of man and animals - summary. Natl Cancer Inst Monograph 1969;32:359-361.
174. Engert A, Sausville EA, Vitetta E. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr Topics Microbiol Immunol 1998;234:13-33.
175. Appelbaum FR, Sale GE, Storb R, Charrier K, Deeg HJ, Graham T, Wulff JC. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. Hematol Oncol 1984;2:151-168.
176. Teske E, Wisman P, Moore PF, van Heerde P. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Exp Hematol 1994; 22:1179-1187.
177. Weir EC, Norrdin RW, Matus RE, Brooks MB, Broadus AE, Mitnick M, Johnston SD, Insogna KL. Humoral hypercalcemia of malignancy in canine lymphosarcoma. Endocrinology 1988;122:602-608.
178. MacEwen EG, Brown NO, Patnaik AK, Hayes AA, Passe S. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.
179. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
180. MacEwen EG, Hayes AA, Matus RE, Kurzman I. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). J Am Vet Med Assoc 1987;190:564-568.
181. Madewell BR. Chemotherapy for canine lymphosarcoma. Am J Vet Res 1975;36:1525-1528.
182. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Pathol 1999;36:292-300.
183. Sarli G, Benazzi C, Preziosi R, Della SL, Bettini G, Marcato PS. Evaluating mitotic activity in canine and feline solid tumors: standardizing the parameter. Biotechnic Histochem 1999;74:64-76.
184. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG, Ritter MA. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp Hematol 1996;24:807-815.
185. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Int Med 1996;10:354-359.
186. Lee JJ, Hughes CS, Fine RL, Page RL. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996;77:1892-1898.
187. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992;80:2315-2320.
188. Dorn CR. Comparative oncology: dogs, cats, and man. Perspect Biol Med 1972;15:507-519.
189. Johnson RE, Cameron TP, Kinard R. Canine lymphoma as a potential model for experimental therapeutics. Cancer Res 1968;28:2562-2564.
190. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990;9:125-136.
191. Yoshimura M, Endo S, Hioki K, Ueyama Y, Ohnishi Y. Chemotherapeutic profiles of human tumors implanted in SCID mice showing appreciable inconsistencies with those in nude mice. Exp Anim Japan Assoc Lab Anim Sci 1997;46:153-156.
192. Fitzgerald D, Pastan I, Robertus J. Clinical applications of immunotoxins. Introduction. Curr Topics Microbiol Immunol 1998;234:1-11.
193. Jansen FK, Blythman HE, Carriere D, Casellas P, Gros O, Gros P, Laurent JC, Paolucci F, Pau B, Poncelet P, Richer G, Vidal H, Voisin GA. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 1982;62:185-216.
194. Blakey DC, Skilleter DN, Price RJ, Thorpe PE. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochim Biophys Acta 1988;968:172-178.
195. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988;48:6396-6403.
196. Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. Leuk Lymphoma 1994;13:441-448.
197. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994;83:1329-1336.
198. Winkler U, Gottstein C, Schon G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 1994;83:466-475.
199. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res 1991;51:5876-5880.
200. Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994;54:4362-4370.
201. Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4 (dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 1999;81:148-155.
202. Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 1993;53:819-825.
203. Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blattler WA. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res 1993;53:1360-1367.
204. Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993;7:298-309.
205. Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br J Cancer 1995;72:1373-1379.
206. Pasqualucci L, Wasik M, Teicher BA, Flenghi I, Bolognesi A, Stirpe F, Polito L, Falini B. Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 1995;85:2139-2146.
207. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, Diehl V, Engert A (2000) Ki-4 (scFv)-ETA, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-3914.
208. Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinkothe T, Lorenzen J, Diehl V, Engert A (2000) Recombinant anti-CD25 immunotoxin RFT5 (SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer 2000;86:718-724.
209. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 1995;85:2537-2545.
210. Ghetie MA, Podar EM, Gordon BE, Pantazis P, Uhr JW, Vitetta ES. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int J Cancer 1996;68:93-96.
211. Liu C, Lambert JM, Teicher BA, Blattler WA, O'Connor R. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996;87:3892-3898.
212. O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995;86:4286-4294.
213. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-6481.
214. O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharmaceut 1998;13:351-361.
215. Engert A, Gottstein C, Bohlen H, Winkler U, Schon G, Manske O, Schnell R, Diehl V, Thorpe P. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 1995;63:304-309.
216. de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. Exp Hematol 1996;24:919-926.
217. Gill I, Agah R, Hu E, Mazumder A. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res 1989;49:5377-5379.
218. Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. Cancer Res 1995;55:840-846.
219. Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995;55:2627-2634.
220. Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rumke P, Melief CJ. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Res 1989;49:3783-3788.
221. O'Boyle KP, Colletti D, Mazurek C, Wang Y, Ray SK, Diamond B, Rosenblum MG, Epstein AL, Shochat D, Dutcher JP. Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor. J Immunother Emph Tumor Immunol 1995;18:221-230.
222. Sondel PM, Hank JA. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. The cancer journal from Sci Am (1997);3 (1 Suppl):S121-S127.
223. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 1999;94:2562-2568.
224. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993;55:830-836.
225. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998;77:763-772.
226. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994;264:833-835.
227. Renner C, Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 1995;145:179-209.
228. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Research 1995;55 (23 Suppl):5832-5836.
229. Manske JM, Buchsbaum DJ, Hanna DE, Vallera DA. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model. Cancer Res 1988;48:7107-7114.
230. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Seminars in oncology 1999;26 (14 Suppl):58-65.
231. Zhu Z, Ghose T, Hoskin D, Lee CL, Fernandez LA, Lee SH, Mammen M. Radioimmunotherapy of human B-cell chronic lymphocytic leukemia in nude mice. Cancer Res 1994;54:5111-5117.
232. DeNardo GL, Kukis DL, Shen S, Mausner LF, Meares CF, Srivastava SC, Miers LA, DeNardo SJ. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3:71-79.
233. Kinuya S, Yokoyama K, Konishi S, Hiramatsu T, Watanabe N, Shuke N, Aburano T, Takayama T, Michigishi T, Tonami N (2000) Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model. Jpn J Cancer Res 2000;91:573-578.
234. Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM. Targeting human cancer xenografts with monoclonal antibodies labeled using radio-iodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res 1999;5 (10 Suppl):3079-3087.
235. Wilder RB, McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radiat Oncol Biol Physics 1994;28:119-126.
236. DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA. Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer 1997;80 (12 Suppl):2576-2582.
237. Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett 1996; 52:145-152.
238. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73 (3 Suppl):787-793.
239. Vriesendorp HM, Quadri SM, Stinson RL, Onyekwere OC, Shao Y, Klein JL, Leichner PK, Williams JR. Selection of reagents for human radioimmunotherapy. Int J Radiat Oncol Biol Physics 1992;22:37-45.
240. Malkovska V, Cigel F, Storer BE. Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity. Clin Exp Immunol 1994;96: 158-165.
241. Katsanis E, Weisdorf DJ, Miller JS. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Bone Marrow Transplant 1998;22: 185-191.
242. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-149.
243. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994;9:3049-3055.
244. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM (2000) Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clinical Cancer Res 2000;6:2492-2500.
245. Mata JE, Joshi SS, Palen B, Pirruccello SJ, Jackson JD, Elias N, Page TJ, Medlin KL, Iversen PL. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol 1997;144:189-197.
246. Cook DR, Maxwell IH, Glode LM, Maxwell F, Stevens JO, Purner MB, Wagner E, Curiel DT, Curiel TJ. Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate. Cancer Biother 1994;9:131-141.